Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model

Abstract Persistent infection with high-risk genotypes of human papillomavirus (HPV) is the leading cause of cervical cancer. The HPV oncoprotein E7 is constitutively expressed in cervical cancer and considered as an essential target for tumor-specific immunity. The goal of this study was to develop...

Full description

Bibliographic Details
Main Authors: Fariba Dorostkar, Arash Arashkia, Farzin Roohvand, Zabihollah Shoja, Mohsen Navari, Maryam Mashhadi Abolghasem Shirazi, Zahra Shahosseini, Mohammad Farahmand, Mohammad Sadegh Shams nosrati, Somayeh Jalilvand
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Infectious Agents and Cancer
Subjects:
Online Access:https://doi.org/10.1186/s13027-021-00346-7
id doaj-a213db6f1d4144389a194dab6e6a2723
record_format Article
spelling doaj-a213db6f1d4144389a194dab6e6a27232021-01-31T12:16:16ZengBMCInfectious Agents and Cancer1750-93782021-01-0116111010.1186/s13027-021-00346-7Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse modelFariba Dorostkar0Arash Arashkia1Farzin Roohvand2Zabihollah Shoja3Mohsen Navari4Maryam Mashhadi Abolghasem Shirazi5Zahra Shahosseini6Mohammad Farahmand7Mohammad Sadegh Shams nosrati8Somayeh Jalilvand9Department of Virology, School of Public Health, Tehran University of Medical SciencesDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Medical Biotechnology, School of Paramedical Sciences, Torbat Heydariyeh University of Medical SciencesDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Virology, School of Public Health, Tehran University of Medical SciencesDepartment of Molecular Virology, Pasteur Institute of IranDepartment of Virology, School of Public Health, Tehran University of Medical SciencesAbstract Persistent infection with high-risk genotypes of human papillomavirus (HPV) is the leading cause of cervical cancer. The HPV oncoprotein E7 is constitutively expressed in cervical cancer and considered as an essential target for tumor-specific immunity. The goal of this study was to develop a candidate therapeutic vaccine based on the mutated E7 protein that had possibly reduced transformation capacity while was able to elicit a robust immune response. Therefore, the mutant type of HPV 16 E7 (E7GRG) protein was recombinantly expressed in E. coli. The protein was then purified and formulated with 2’-3’cGAMP CDN and/or CpG-C ODN adjuvants and subcutaneously injected to female C57BL/6 mice. To evaluate the immunogenic response, lymphocyte proliferation, secretion levels of IFN-γ and IL-4 cytokines, granzyme B level, and total IgG and subclasses of IgG antibody were measured. The anti-tumor activity was evaluated in tumor-harboring C57BL/6 mice. The highest rate of cell proliferation, IFN-γ and granzyme B levels, and amount of IgG antibody were found in mice group that were injected by E7GRG + 2′-3′cGAMP + CpG-C. Therapeutic immunization with E7GRG + 2′-3′cGAMP + CpG-C also significantly suppressed TC-1 tumor growth in mice. In conclusion, the results demonstrated that E7GRG + 2′-3′cGAMP + CpG-C induced strong cell-mediated and humoral immune responses that resulted in inhibition of tumor in mouse model.https://doi.org/10.1186/s13027-021-00346-7Human papillomavirusHPV vaccineE7 oncoproteinStimulator of interferon genesSTINGCpG ODN 2395
collection DOAJ
language English
format Article
sources DOAJ
author Fariba Dorostkar
Arash Arashkia
Farzin Roohvand
Zabihollah Shoja
Mohsen Navari
Maryam Mashhadi Abolghasem Shirazi
Zahra Shahosseini
Mohammad Farahmand
Mohammad Sadegh Shams nosrati
Somayeh Jalilvand
spellingShingle Fariba Dorostkar
Arash Arashkia
Farzin Roohvand
Zabihollah Shoja
Mohsen Navari
Maryam Mashhadi Abolghasem Shirazi
Zahra Shahosseini
Mohammad Farahmand
Mohammad Sadegh Shams nosrati
Somayeh Jalilvand
Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model
Infectious Agents and Cancer
Human papillomavirus
HPV vaccine
E7 oncoprotein
Stimulator of interferon genes
STING
CpG ODN 2395
author_facet Fariba Dorostkar
Arash Arashkia
Farzin Roohvand
Zabihollah Shoja
Mohsen Navari
Maryam Mashhadi Abolghasem Shirazi
Zahra Shahosseini
Mohammad Farahmand
Mohammad Sadegh Shams nosrati
Somayeh Jalilvand
author_sort Fariba Dorostkar
title Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model
title_short Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model
title_full Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model
title_fullStr Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model
title_full_unstemmed Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model
title_sort co‐administration of 2’3’-cgamp sting activator and cpg-c adjuvants with a mutated form of hpv 16 e7 protein leads to tumor growth inhibition in the mouse model
publisher BMC
series Infectious Agents and Cancer
issn 1750-9378
publishDate 2021-01-01
description Abstract Persistent infection with high-risk genotypes of human papillomavirus (HPV) is the leading cause of cervical cancer. The HPV oncoprotein E7 is constitutively expressed in cervical cancer and considered as an essential target for tumor-specific immunity. The goal of this study was to develop a candidate therapeutic vaccine based on the mutated E7 protein that had possibly reduced transformation capacity while was able to elicit a robust immune response. Therefore, the mutant type of HPV 16 E7 (E7GRG) protein was recombinantly expressed in E. coli. The protein was then purified and formulated with 2’-3’cGAMP CDN and/or CpG-C ODN adjuvants and subcutaneously injected to female C57BL/6 mice. To evaluate the immunogenic response, lymphocyte proliferation, secretion levels of IFN-γ and IL-4 cytokines, granzyme B level, and total IgG and subclasses of IgG antibody were measured. The anti-tumor activity was evaluated in tumor-harboring C57BL/6 mice. The highest rate of cell proliferation, IFN-γ and granzyme B levels, and amount of IgG antibody were found in mice group that were injected by E7GRG + 2′-3′cGAMP + CpG-C. Therapeutic immunization with E7GRG + 2′-3′cGAMP + CpG-C also significantly suppressed TC-1 tumor growth in mice. In conclusion, the results demonstrated that E7GRG + 2′-3′cGAMP + CpG-C induced strong cell-mediated and humoral immune responses that resulted in inhibition of tumor in mouse model.
topic Human papillomavirus
HPV vaccine
E7 oncoprotein
Stimulator of interferon genes
STING
CpG ODN 2395
url https://doi.org/10.1186/s13027-021-00346-7
work_keys_str_mv AT faribadorostkar coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel
AT arasharashkia coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel
AT farzinroohvand coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel
AT zabihollahshoja coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel
AT mohsennavari coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel
AT maryammashhadiabolghasemshirazi coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel
AT zahrashahosseini coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel
AT mohammadfarahmand coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel
AT mohammadsadeghshamsnosrati coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel
AT somayehjalilvand coadministrationof23cgampstingactivatorandcpgcadjuvantswithamutatedformofhpv16e7proteinleadstotumorgrowthinhibitioninthemousemodel
_version_ 1724317425651941376